Increased Risk of High-Grade Hemorrhage in Cancer Patients Treated with Gemcitabine: A Meta-Analysis of 20 Randomized Controlled Trials

Open Access

Peer-reviewed

Research Article

Yi Hu ,

* E-mail: huyi20130502@163.com

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯
Jingliang Wang,

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯
Haitao Tao,

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯
Baishou Wu,

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯
Jin Sun,

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯
Yao Cheng,

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯
Weiwei Dong,

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯
Ruixin Li

Affiliation Department of Oncology, Chinese PLA General Hospital, BeiJing City, People’s Republic of China
⨯

Reader Comments (0)

Hemorrhage
Is the Subject Area "Hemorrhage" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Cancer risk factors
Is the Subject Area "Cancer risk factors" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cancer epidemiology
Is the Subject Area "Cancer epidemiology" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Phase II clinical investigation
Is the Subject Area "Phase II clinical investigation" applicable to this article?

Thanks for your feedback.